Novartis scored a win in litigation over one of the patents underlying its cancer treatment Afinitor, as a federal appeals court on Monday rejected arguments by the would-be maker of a generic version that the patent is invalid.
Novartis defeats challenge to validity of Afinitor patent
More from Pharma NewsMore posts in Pharma News »
- Brazil coronavirus deaths climb to 46,510, cases near 1 million
- Requiring masks ‘political hazard’ as COVID-19 surges in California breadbasket
- Mothers as ‘trauma surgeons:’ the anguish of raising black boys in America
- Record spike in new coronavirus cases reported in six U.S. states as reopening accelerates